person · Reporting owner

Panayiotopoulos Paris

Disclosed activity across 3 companies

Tapewire entity: 152554
SEC CIK: 0001662996

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261	Director	May 22, 2019	June 28, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Corbus Pharmaceuticals Holdings, Inc.

Report date May 22, 2019 · Filed June 28, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 2029-05-22	Direct	33,300	Reported balance After 2019-05-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-22 · Grant · Acquired 33,300 · Balance 33,300 F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARIAD PHARMACEUTICALS INC

Report date February 16, 2017 · Filed February 16, 2017

Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-02-16 transaction · row 1 1 source row Row 1 · 2017-02-16 · Disposition to issuer · Disposed 159,378 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.34	Direct	Reported balance After 2017-02-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-02-16 · Disposition to issuer · Disposed 1,500,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2017-02-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-16 · Disposition to issuer · Disposed 66,800 · Balance 0 F3: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.

F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

F3: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.

MEDICINES CO /DE

Report date January 06, 2020 · Filed January 06, 2020

Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-06 transaction · row 1 1 source row Row 1 · 2020-01-06 · Disposition to issuer · Disposed 13,881 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $51.02	Direct	Reported balance After 2020-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-06 · Disposition to issuer · Disposed 16,559 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $39.39	Direct	Reported balance After 2020-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-06 · Disposition to issuer · Disposed 8,577 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.86	Direct	Reported balance After 2020-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-06 · Disposition to issuer · Disposed 9,141 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.81	Direct	Reported balance After 2020-01-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-06 · Disposition to issuer · Disposed 8,410 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price").

F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.

F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 06, 2020 Filed Jan 6, 2020 13:29 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	8,410	$0.00 Strike: $34.81	$0.00	Disclosure SEC source: 0000950142-20-000046 · es2000131_4-panayiotopoulos.xml · derivative · entry 5 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,410 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:29 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	9,141	$0.00 Strike: $33.86	$0.00	Disclosure SEC source: 0000950142-20-000046 · es2000131_4-panayiotopoulos.xml · derivative · entry 4 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,141 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:29 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	8,577	$0.00 Strike: $39.39	$0.00	Disclosure SEC source: 0000950142-20-000046 · es2000131_4-panayiotopoulos.xml · derivative · entry 3 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,577 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:29 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	16,559	$0.00 Strike: $51.02	$0.00	Disclosure SEC source: 0000950142-20-000046 · es2000131_4-panayiotopoulos.xml · derivative · entry 2 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,559 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:29 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerCommon Stock	13,881	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-20-000046 · es2000131_4-panayiotopoulos.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2 · price: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share. Read SEC document
May 30, 2019 Filed Jun 3, 2019 17:13 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Option (right-to-buy) · Derivative	8,410	$0.00 Strike: $34.81	$0.00	Disclosure SEC source: 0001179110-19-007028 · edgar.xml · derivative · entry 2 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,410 Underlying: Common Stock · 8,410 shares Expires 2029-05-30 F2 · derivative.exercise_date: The option vests in one installment on May 30, 2020 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 30, 2019 Filed Jun 3, 2019 17:13 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,663	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007028 · edgar.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,881 F1 · shares: The restricted stock award vests on May 30, 2020 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 22, 2019 Filed Jun 28, 2019 20:06 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option(right to buy) · Derivative	33,300	$0.00 Strike: $7.31	$0.00	Disclosure SEC source: 0001209191-19-039469 · doc4.xml · derivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,300 Underlying: Common Stock · 33,300 shares Expires 2029-05-22 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
May 31, 2018 Filed Jun 4, 2018 16:53 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Option (right-to-buy) · Derivative	9,141	$0.00 Strike: $33.86	$0.00	Disclosure SEC source: 0001179110-18-007956 · edgar.xml · derivative · entry 2 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,141 Underlying: Common Stock · 9,141 shares Expires 2028-05-31 F2 · derivative.exercise_date: The option vests in one installment on May 31, 2019 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 31, 2018 Filed Jun 4, 2018 16:53 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,766	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007956 · edgar.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,218 F1 · shares: The restricted stock award vests on May 31, 2019 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 24, 2018 Filed May 29, 2018 20:11 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option(right to buy) · Derivative	34,000	$0.00 Strike: $5.93	$0.00	Disclosure SEC source: 0001209191-18-033781 · doc4.xml · derivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-05-24 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
November 30, 2017 Filed Dec 1, 2017 17:47 UTC	MEDICINES CO /DE MDCO · Entity 152552	PurchaseCommon Stock	3,215	$30.97	$99,568.55	Disclosure SEC source: 0001179110-17-014789 · edgar.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,452 Read SEC document
November 16, 2017 Filed Nov 17, 2017 15:04 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	PurchaseCommon Stock	14,285	$7.03	$100,392.12	Disclosure SEC source: 0001209191-17-061358 · doc4.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,285 Read SEC document
October 16, 2017 Filed Oct 18, 2017 11:50 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option(right to buy) · Derivative	61,000	$0.00 Strike: $6.90	$0.00	Disclosure SEC source: 0001209191-17-057230 · doc4.xml · derivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 61,000 shares Expires 2027-10-16 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
May 25, 2017 Filed May 30, 2017 19:40 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Option (right-to-buy) · Derivative	8,577	$0.00 Strike: $39.39	$0.00	Disclosure SEC source: 0001179110-17-008215 · edgar.xml · derivative · entry 2 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Underlying: Common Stock · 8,577 shares Expires 2017-05-25 F2 · derivative.exercise_date: This option vests in one installment on May 25, 2018 and is made as part of and pursuant to Issuer's director compensation package. Read SEC document
May 25, 2017 Filed May 30, 2017 19:40 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,237	$0.00	$0.00	Disclosure SEC source: 0001179110-17-008215 · edgar.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,237 F1 · shares: This restricted stock award vests on May 25, 2018 and is made as part of and pursuant to Issuer's director compensation package. Read SEC document
March 28, 2017 Filed Mar 31, 2017 14:42 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCall Option (right-to-buy) · Derivative	16,559	$0.00 Strike: $51.02	$0.00	Disclosure SEC source: 0001179110-17-005296 · edgar.xml · derivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,559 Underlying: Common Stock · 16,559 shares Expires 2027-03-28 F1 · derivative.exercise_date: This option vests in one installment on March 28, 2027 and is made part of and pursuant to Issuer's director compensation package. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:15 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerRestricted Stock Units · Derivative	66,800	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000884731-17-000051 · wf-form4_148727251700389.xml · derivative · entry 3 Panayiotopoulos Paris · CIK 0001662996 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,800 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:15 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	1,500,000	$0.00 Strike: $5.34	$0.00	Disclosure SEC source: 0000884731-17-000051 · wf-form4_148727251700389.xml · derivative · entry 2 Panayiotopoulos Paris · CIK 0001662996 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires not disclosed F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:15 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerCommon Stock	159,378	Not disclosed	Not disclosed	Disclosure SEC source: 0000884731-17-000051 · wf-form4_148727251700389.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. Read SEC document
January 17, 2017 Filed Jan 17, 2017 17:06 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Tax withholdingCommon Stock	33,300	$23.69	$788,933.61	Disclosure SEC source: 0000884731-17-000004 · wf-form4_148469079934747.xml · nonDerivative · entry 2 Panayiotopoulos Paris · CIK 0001662996 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,378 F2 · kind: Represents shares sold to satisfy withholding tax requirements pursuant to a Rule 10b5-1 trading plan adopted June 15, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.67 to $23.72, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 13, 2017 Filed Jan 17, 2017 17:06 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Exercise / conversionRestricted Stock Units · Derivative	66,600	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000884731-17-000004 · wf-form4_148469079934747.xml · derivative · entry 3 Panayiotopoulos Paris · CIK 0001662996 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,800 Underlying: Common Stock · 66,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This RSU vests as to approximately one third of the award on each of July 13, 2016, January 13, 2017 and July 13, 2017. F5 · derivative.expiration_date: N/A Read SEC document
January 13, 2017 Filed Jan 17, 2017 17:06 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Exercise / conversionCommon Stock	66,600	$0.00	$0.00	Disclosure SEC source: 0000884731-17-000004 · wf-form4_148469079934747.xml · nonDerivative · entry 1 Panayiotopoulos Paris · CIK 0001662996 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon the vesting of a Restricted Stock Unit previously granted on January 13, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.